Record mula sa primary source
Decision-gradeIba pa
Inanunsyo ng HOWL/Ambros ang pagsasanib at $150M na placement para pondohan ang Phase 3 ng neridronate
Werewolf Therapeutics at Ambros Therapeutics ay pumirma ng tiyak na kasunduan sa pagsasanib na all-stock na lilikha ng isang Nasdaq-listed entity na nakatuon sa neridronate para sa CRPS-1. Ang kasabay na oversubscribed na $150 million private placement ay magpopondo sa patuloy na pivotal CRPS-RISE Phase 3 trial hanggang sa topline readout sa 2028 at planadong NDA submission, na may cash runway hanggang 1H 2029.
Mahahalagang fact
- Na-file
- Ago 21, 2026, 01:10 PM
- Kaganapan
- Iba pa
- Direksyon
- Positibo
- Kumpanya
HOWLWerewolf Therapeutics- Asset
- neridronate
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Taning ng pondo
- 1H 2029
- Pagsumite ng NDA
- planado
- topline inaasahan
- 2028
- Pribadong pag-aalok ng bahagi
- 150 milyon
- Eksklusibong karapatan sa merkado
- 2045
- Mga kalahok sa Phase 3
- 270
- bagong diagnosed na pasyente sa us
- 65000
Sipi mula sa source
EX-99.1 11 d102535dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Werewolf Therapeutics at Ambros Therapeutics Nag-anunsyo ng Kasunduan sa Pagsasanib at Kasabay na Oversubscribed $150 million Private Placement • Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapy • Pivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and alignment with FDA that a single successful pivotal trial could potentially support approval • Neridronate has been administered to approximately 600,000 pati